|
|
|
| Influence of Chinese herbal colon dialysis on intestinal “microecology” in patients of dampness-turbidity blood stasis syndrome with stage three to four chronic kidney disease |
| ZHANG Qian LI Tongxia▲ HUANG Xueying YAN Pu SHI Kaifeng WANG Xin HOU Hailing |
Department of Nephroendocrinology, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China
|
|
|
|
Abstract Objective To investigate the influence of Chinese herbal colon dialysis on intestinal “microecology” in patients of dampness-turbidity blood stasis syndrome with stage three to four chronic kidney disease. Methods One hundred and eight outpatients and inpatients from the Department of Nephroendocrinology, Wangjing Hospital of China Academy of Chinese Medical Sciences from April 2018 to August 2020 were selected and divided into control group and test group according to the district group, with 54 patients in each group. Both groups were given basic treatment, control group was given routine colon dialysis, and test group was given Chinese herbal colon dialysis, once every other day, for four weeks. Indoxyl sulfate, blood creatinine, urea nitrogen, estimated glomerular filtration rate (eGFR), serum endotoxin, D-lactic acid, Escherichia coli, Bifidobacterium of two groups were compared before and after treatment. Results Control group lost seven cases and test group lost five cases. Before treatment, there were no significant differences between the two groups in indoxyl sulfate, blood creatinine, urea nitrogen, and eGFR (P＞0.05). After treatment, the levels of indoxyl sulfate, blood creatinine, and urea nitrogen in the two groups were lower than those before treatment, and the eGFR in the two groups was higher than that before treatment, and the levels of indoxyl sulfate, blood creatinine, and urea nitrogen in test group were lower than those in control group, and the eGFR in test group was higher than that in control group, with statistically significant differences (P＜0.05). Before treatment, there were no significant differences between the two groups in serum endotoxin, D-lactic acid, and Escherichia coli (P＞0.05). After treatment, the serum endotoxin and D-lactic acid in the two groups were lower than those before treatment, and test group was lower than that control group, the differences were statistically significant (P＜0.05). After treatment, the number of Escherichia coli in test group was less than that before treatment and that in control group, the differences were statistically significant (P＜0.05). Before and after treatment, there was no significant difference in the inter-group and intra-group comparison of Bifidobacteria between the two groups (P＞0.05). Conclusion Chinese herbal colon dialysis can effectively reduce uremic toxin, improve the intestinal “microecology” of patients with chronic kidney disease, and delay the progression of renal function.
|
|
|
|
|
|
[1] Glassock RJ，Warnock DG，Delanaye P. The global burden of chronic kidney disease：estimates，variability and pitfalls [J]. Nat Rev Nephrol，2017，13（2）：104-114.
[2] Bikbov B，Purcell CA，Levey AS，et al. Global，regional，and national burden of chronic kidney disease，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2020，395（10225）：709-733.
[3] Hobby GP，Karaduta O，Dusio GF，et al. Chronic kidney disease and the gut microbiome [J]. Am J Physiol Renal Physiol，2019，316（6）：F1211-F1217.
[4] Rysz J，Franczyk B，J Awiński，et al. The Impact of CKD on uremic toxins and gut microbiota [J]. Toxins，2021，13（4）：252.
[5] 冯文涛，韩耀国，孙芳园，等.中药灌肠法的临床应用研究进展[J].世界中西医结合杂志，2020，15（8）：1565-1568.
[6] Levin A，Stevens PE，Bilous RW，et al. Kidney disease：improving global outcomes （KDIGO） CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease [J]. Kidney Int Supplements，2013，3（1）：1-150.
[7] 陈香美，倪兆慧，刘玉宁，等.慢性肾衰竭中西医结合诊疗指南[J].中国中西医结合杂志，2015，35（9）：1029-1033.
[8] Inker LA，Schmid CH，Tighiouart H，et al. Estimating glomerular filtration rate from serum creatinine and cystatin C [J]. N Engl J Med，2012，367（1）：20-29.
[9] 白雪莲，张佳宜，项国梁，等.中国成人慢性肾脏病患病率的meta分析[J].中国医药科学，2022，12（9）：49-53.
[10] 田海刚.慢性肾脏病中医证候学研究[D].北京：北京中医药大学，2009.
[11] 甄苗苗.肾衰灌肠方治疗慢性肾功能衰竭的临床研究[D].北京：北京中医药大学，2016.
[12] 易庆莲，王亿平，梁晓平.中药肠道疗法在慢性肾脏病治疗中的应用[J].中医药临床杂志，2020，32（12）：2213- 2217.
[13] Wu L，Wang Y，Liu Y，et al. Efficacy and safety of traditional Chinese medicinal enemas for treatment of chronic renal failure：a protocol for systematic review and meta- analysis [J]. Medicine，2020，99（44）：e23002.
[14] Gryp T，Paepe KD，Vanholder R，et al. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease [J]. Kidney Int，2020，97（6）：1230-1242.
[15] Vanholder R，Gryp T，Glorieux G. Urea and chronic kidney disease：the comeback of the century? （in uraemia research） [J]. Nephrol Dial Transplant，2018，33（1）：4-12.
[16] Rosner MH，Reis T，Husain-Syed F，et al. Classification of uremic toxins and their role in kidney failure [J]. Clin J Am Soc Nephrol，2021，16（12）：1918-1928.
[17] Cheng TH，Ma MC，Liao MT，et al. Indoxyl sulfate，a tubular toxin，contributes to the development of chronic kidney disease [J]. Toxins，2020，12（11）：684.
[18] Hung S，Kuo K，Wu C，et al. Indoxyl sulfate：a novel cardiovascular risk factor in chronic kidney disease [J]. J Am Heart Assoc，2017，6（2）：e005022.
[19] 曾玉群.大黄及其活性物质灌肠对慢性肾脏病模型大鼠作用的分子机制[D].广州：广州中医药大学，2017.
[20] Ramezani A，Massy ZA，Meijers B，et al. Role of the gut microbiome in uremia：a potential therapeutic target [J]. Am J Kidney Dis，2016，67（3）：483-498.
[21] Jiang S，Xie S，Lv D，et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease [J]. Sci Rep，2017，7（1）：2870.
[22] 胥振国，蔡玉华，刘修树，等.双歧杆菌研究进展及应用前景[J].中国生物制品学杂志，2017，30（2）：215-220.
[23] Vacca M，Celano G，Lenucci MS，et al. In vitro selection of probiotics，prebiotics，and antioxidants to develop an innovative synbiotic （NatuREN G） and testing its effect in reducing uremic toxins in fecal batches from CKD patients [J]. Microorganisms，2021，9（6）：1316.
[24] 汪慧霞，张彩凤，张超群，等.益生菌治疗幽门螺杆菌阳性胃溃疡的效果及对肠道菌群分布、血清炎症因子的影响[J].中国医药导报，2021，18（12）：154-158.
[25] Rossi M，Johnson DW，Morrison M，et al. Synbiotics easing renal failure by improving gut microbiology （SYNERGY）：a randomized trial [J]. Clin J Am Soc Nephrol，2016，11（2）：223-231.
[26] 韩卓君，吴小平，严明煜，等.中药与肠道菌群相互作用机制探讨[J].世界中医药，2021，16（24）：3591-3595.
[27] 尉浩斌，张小丹，李苏宜.肠屏障功能损伤机制及其临床检测方法研究现状[J].肿瘤代谢与营养电子杂志，2020， 7（4）：407-414.
[28] 程源.D-乳酸与I-FABP在肠屏障功能受损中作用的研究进展[J].中国临床新医学，2018，11（9）：949-953. |
|
|
|
